Roche Diagnostics Launches First Domestically Produced Pathology Platform in China: BenchMark ULTRA PLUS
Roche
Oncology Drug Research, Development, and Manufacturing
Source: Roche Diagnostics
Recently, Roche Diagnostics China announced,China-produced Fully Automatic Immunohistochemistry Staining Platform BenchMark ULTRA PLUS Officially Approved, and will be officially put into production at Roche Diagnostics' Asia-Pacific production base and R&D center. As the first domestically produced pathology diagnostics platform launched by Roche Diagnostics, the debut of the domestically produced BenchMark ULTRA PLUS marks a breakthrough achievement for "Made in China" in the field of pathology diagnostics. This is another significant milestone in Roche Diagnostics' ongoing commitment to local innovation.
Deeply Rooted in China, Driving Innovation, Empowering the Future
As the "gold standard" for disease diagnosis, the significant value of accurate and efficient pathological diagnosis in the era of precision medicine is becoming increasingly prominent. As a global leader in the field of pathological diagnosis, since entering the Chinese pathology market with VENTANA in 2009, Roche Diagnostics has been committed to providing cutting-edge pathology diagnostic solutions and services, continuously injecting innovative momentum into the high-quality development of pathology diagnostics in China.
To promote the automated and standardized development of pathology laboratories in China, achieving more standardized laboratory quality control and management:
China's First BenchMark Fully Automated Immunohistochemistry Staining Platform Successfully Launched, Marking a Milestone Shift from "Manual" to "Automated" in Pathological Staining and Opening a New Era of Pathological Diagnosis in China.
The number of installations of the BenchMark series platform has exceeded 1,000 sets.
The number of installed customers for the BenchMark series platform has exceeded 1,000, with a total of more than 2,000 installations. It has gained widespread market recognition due to its unique technology and excellent quality.
The all-new BenchMark ULTRA PLUS platform makes a significant debut in China, further advancing the standardization, refinement, and intelligent development of pathology testing with multiple innovative upgrades.
On the 15th anniversary of Roche Diagnostics' official entry into China's pathology market, the launch of the domestically produced BenchMark ULTRA PLUS will further meet the needs of high-quality development in China’s pathology laboratories, providing patients with more precise and efficient pathology diagnostic services.
This time, the domestically produced BenchMark ULTRA PLUS platform will be localized for production at Roche Diagnostics' Asia-Pacific production base and R&D center located in Suzhou. The production quality management system of this production base and R&D center is established according to Roche's globally unified standards, possessing a complete R&D and manufacturing industrial chain as well as functions such as warehousing and logistics. The entire production process, technology, raw materials, and formulations are maintained at the same standards as Roche’s original factory to ensure that Roche Diagnostics' "Made in China" becomes synonymous with a global quality benchmark.
Disclaimer: The articles published on this WeChat platform that are cited from other sources are reprinted for the purpose of sharing only, and do not represent the position of the platform. If there are any copyright issues or other problems, please contact us as soon as possible, and we will make corrections immediately. Thank you.